Week in Review: BeiGene Announces $75 Million Series A Fundraising

BeiGene, a Beijing biotech with three oncology drugs in Phase I trials, raised $75 million in a series A funding; Ascletis in-licensed China rights to a clinical-stage hepatitis C treatment from Presidio of San Francisco; BioAtla, a San Diego-China drugmaker, will collaborate with China CRO BioDuro to develop two therapeutic monoclonal antibodies in China; Taiwanese drugmaker ScinoPharm teamed up with Nanjing King-friend Biochemical to develop an imaging drug for China; Sinopharm and Provectus Biopharma of the US extended their MOU on a cancer immunotherapy; China's Center for Drug Evaluation published its long-awaited draft regulations for approval of biosimilar drugs; WuXi PharmaTech reported Q3 revenues were up 18% while earnings were higher by 8%; and CASI Pharma received permission to start a Phase II trial of its lead cancer drug in China. More details.... Stock Symbols: (TWSE: 1789) (NYSE: PVCT) (NYSE: WX) (NSDQ: CASI) Share this with colleagues: // //